Albuminuria-lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: A randomized and placebo-controlled study

What Was Tested

The paper reports a study of Semaglutide, published as a randomized controlled trial.

Who Took Part

The abstract describes 60 individuals taking part.

How the Study Was Run

The design is described as randomized, double-blind, open-label, placebo-controlled and parallel-group.

Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.

As a double-blind Semaglutide study, the assignments were hidden from both participants and investigators until the end.

Everyone knew when Semaglutide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

A placebo (an inactive look-alike) gave the Semaglutide group a baseline to be compared against.

The researchers conducted a randomized, placebo-controlled, double-blind, parallel study including 60 individuals with T2D and albuminuria.

The primary endpoint was change in UACR.

Secondary endpoints were change in: (i) measured glomerular filtration rate (GFR); (ii) 24-hour systolic blood pressure; (iii) glycated haemoglobin (HbA1c) level; (iv) body weight; and (v) plasma renin and aldosterone levels.

What Was Measured

PubMed files the paper under topics including Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Glycated Hemoglobin, Albuminuria, Renin, Aldosterone and Glucagon-Like Peptides.

Author keywords: GLP-1 analogue, SGLT2 inhibitor, diabetic nephropathy and randomized trial.

What This Means in Plain Language

The paper is a randomized, double-blind and open-label study of Semaglutide in 60 individuals.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2024 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Semaglutide compound page, all human trials.